ロード中...

Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer

Dermatologic adverse events (dAEs) are common with the use of epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) therapy. First‐ and second‐generation agents (erlotinib, gefitinib, and afatinib) are frequently associated with acneiform rash, pruritus, xerosis, and paronychia; the...

詳細記述

保存先:
書誌詳細
出版年:Oncologist
主要な著者: Chu, Chia‐Yu, Choi, Jennifer, Eaby‐Sandy, Beth, Langer, Corey J., Lacouture, Mario E.
フォーマット: Artigo
言語:Inglês
出版事項: AlphaMed Press 2018
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6156184/
https://ncbi.nlm.nih.gov/pubmed/29650685
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0582
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!